Outcomes and Cosmesis With Whole Breast Irradiation and Boost
This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.
- EligibilityCriteria: Inclusion Criteria:  Ability to understand and the willingness to sign a written informed consent document Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques Treatment plan includes breast tumor bed boost Willingness to comply with all study procedures and be available for the duration of the study  Exclusion Criteria:  Mastectomy of ipsilateral breast Lack of histologic diagnosis Histologic involvement of the axillary or regional nodes or metastatic disease Accelerated partial breast irradiation treatment plan Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin Previous history of chest radiation therapy Previous history of ipsilateral breast cancer Concurrent cytotoxic chemotherapy Active connective tissue disease including scleroderma Inability or unwillingness to return for required follow up visit - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult